Pieter brings a wealth of expertise spanning over 20 years in the realms of flow chemistry, radiopharmaceutical instrumentation, and automation design. Notably, he is an inventor on 7 patents. Pieter completed a Masters degree and a PhD at Radboud University Nijmegen, with a specialization in Organic Chemistry. His groundbreaking research during his doctoral studies focused on the pioneering implementation of microreactor technology in organic chemistry, becoming the foundation of FutureChemistry’s (former) IP portfolio.
One of Pieter’s notable strengths lies in his vast experience in designing automated laboratory equipment and a comprehensive understanding of Good Manufacturing Practices (GMP). His commitment to precision and efficiency in scientific processes has been instrumental in the direction of the company.
Currently, Pieter’s pivotal role at FutureChemistry encompasses key responsibilities in team management, intellectual property management, instrumentation design, and automation.
With 15 years of distinguished expertise in developing radiolabelling and purification methods, Dion possesses a wealth of radionuclide experience, including C-11, F-18, Ga-68, I-123, Lu-177, Pt-195m, At-211, and Pb-212.
Throughout his academic journey, Dion undertook a PhD at the VU University Medical Centre. His pioneering work centered on developing a novel methodology for incorporating a fluorine-18 labelled trifluoromethyl (CF3) functional group onto aromatic compounds. This groundbreaking approach paved the way for the radiolabelling and thorough biological evaluation of drugs and drug candidates containing the CF3 group.
As radiochemist at FutureChemistry, Dion’s contributions are pivotal in delivering tailored radiochemistry solutions to clients. His expertise spans labelling, purification, and meticulous documentation, enabling the advancement of cutting-edge radiopharmaceutical research and applications.
James received a Bachelor of Commerce in Corporate Finance from the University of Western Australia and a Bachelor of Science and PhD from The University of Queensland in the field of Medicinal and Radiopharmaceutical Chemistry. Additionally, he spent one year at the University of Michigan on a Fulbright Scholarship. Throughout his education and training, he gained substantial hands-on experience developing carbon-11 and fluorine-18 tracers for positron emission tomography.
James moved to the Netherlands, to continue work with carbon-11 and fluorine-18, undertaking postdoctoral research at Amsterdam University Medical Centre (VU). Following this, James worked as an Innovation Consultant, helping companies acquire > € 8 M in subsidy funding.
Now, at FutureChemistry, James spearheads the development of radiolabelling services and fosters collaborative partnerships within the industry. Additionally, he plays a crucial role in assisting with funding applications, leveraging his unique blend of financial and scientific knowledge to propel the company’s growth and success.